In searching the literature, we noted that increased expression of the B lymphocyte-induced maturation protein 1 (Blimp-1) transcription factor could similarly regulate many of the phenotypic changes induced by HMA/venetoclax in our AML patients. The gene discussed is PRDM1; the disease is acute myeloid leukemia.